(BUSINESS WIRE)--Zalicus Inc. today announced plans for advancing the development of product candidates from its internal pipeline focused in the core areas of pain and inflammation, including Synavive™ for rheumatoid arthritis (RA) and multiple compounds from its Ion channel program for the treatment of pain. In addition, Novartis has exercised its first option to extend its oncology discovery research collaboration with Zalicus for an additional contract year. Zalicus will continue to actively pursue additional research collaborations to utilize its proprietary combination high-throughput screening (cHTS) and Ion channel technology platforms.
